Nuvig Therapeutics Appoints Celia J.F. Lin, M.D., as Chief Medical Officer, Strengthening Clinical Leadership Amid Advancement of Novel Immunomodulatory Programs Nuvig Therapeutics, Inc. (“Nuvig”), a privately held biotechnology company focused…
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Lead Global Strategy for BOT/BAL and Early-Access Programs Agenus Inc. (Nasdaq: AGEN), a biotechnology company recognized for its long-standing…
Enanta Pharmaceuticals Reports Fiscal Fourth Quarter and Full-Year 2025 Financial Results and Highlights Major Clinical Advancements Across Virology and Immunology Programs Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company…
CorriXR Therapeutics Announces Publication of Preclinical Data Demonstrating the Potential of CRISPR-Directed Gene Editing to Overcome Drug Resistance in Solid Tumors CorriXR Therapeutics, Inc., an oncology-focused biotherapeutics company advancing a…
Sonoma Biotherapeutics Announces Leadership Transition as Stephen Dilly, MBBS, PhD, Becomes President and CEO; Co-founder Jeff Bluestone, PhD, Assumes Advisory Role Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company advancing engineered…
Solve Therapeutics Raises $120 Million to Accelerate Next-Generation ADC Development for Solid Tumors Solve Therapeutics, a rapidly advancing clinical-stage biotechnology company focused on creating best-in-class antibody–drug conjugates (ADCs) for the…
Scribe Therapeutics Highlights Major ASCVD Lipid Insights at AHA 2025 Scribe Therapeutics Inc. (“Scribe”), a leading genetic medicines company engineering next-generation in vivo CRISPR-based treatments, unveiled a series of breakthrough…
Johnson & Johnson Strengthens Oncology Leadership With $3.05 Billion Acquisition of Halda Therapeutics and Its Next-Generation RIPTAC™ Platform Johnson & Johnson (NYSE: JNJ) announced that it has entered into a…
JSR Life Sciences Announces Definitive Agreement to Transfer Crown Bioscience to Adicon Holdings, Marking a Significant Strategic Realignment in Oncology Research Services JSR Life Sciences LLC (“JSR Life Sciences”), a…
Inflammasome Therapeutics to Collaborate with Healey & AMG Center on New ALS Treatment Study Inflammasome Therapeutics, a clinical-stage biotechnology company advancing a new category of drug candidates known as Kamuvudines…
Flightpath Biosciences Advances Precision Anti-Infective Strategy with New Drug License and Corporate Rebrand as Company Enters Next Phase of Growth Flightpath Biosciences, a clinical-stage biotechnology company committed to developing innovative…
New Survey Shows NMIBC Patients Want More Inclusive Care Conversations and Greater Awareness of Emerging Treatment Options A new national survey conducted in the United States by The Harris Poll,…